The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jovasevic, V. M.
Right arrow Articles by Mokyr, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jovasevic, V. M.
Right arrow Articles by Mokyr, M. B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*MELPHALAN
The Journal of Immunology, 2004, 172: 1449-1454.
Copyright © 2004 by The American Association of Immunologists

Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity1

Vladimir M. Jovasevic*, Leonid Gorelik2,*, Jeffrey A. Bluestone{dagger} and Margalit B. Mokyr3,*

* Department of Biochemistry and Molecular Genetics, University of Illinois, Chicago, IL 60612; and {dagger} Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143

In this study, we show that engagement of CTLA-4 on tumor-infiltrating lymphocytes from low-dose melphalan (L-phenylalanine mustard (L-PAM))-treated MOPC-315 tumor bearers led to IL-10 secretion. In addition, the inhibitory activity of CTLA-4 ligation for IFN-{gamma} secretion following stimulation with anti-CD3 plus anti-CD28 mAb depended on IL-10 production. Consistent with the importance of IL-10 for CTLA-4-mediated inhibition, administration of neutralizing anti-IL-10 mAb to low-dose L-PAM-treated MOPC-315 tumor bearers (administration of blocking anti-CTLA-4 mAb) resulted in enhanced tumor-infiltrating lymphocyte-mediated anti-MOPC-315 cytotoxicity and led to complete tumor eradication in a higher percentage of mice than that observed with low-dose L-PAM alone. The percentage of MOPC-315 tumor-bearing mice cured following administration of neutralizing anti-IL-10 mAb to low-dose L-PAM-treated MOPC-315 tumor bearers was comparable to that observed following administration of blocking anti-CTLA-4 mAb. Moreover, IL-10 neutralization together with CTLA-4 blockade did not provide added therapeutic benefits to low-dose L-PAM-treated MOPC-315 tumor bearers. Taken together, these results indicate that CTLA-4 blockade improves the therapeutic outcome of low-dose L-PAM for MOPC-315 tumor bearers by inhibiting IL-10 secretion as a consequence of blocking CTLA-4 ligation.




This article has been cited by other articles:


Home page
J. Immunol.Home page
N. Perez, S. Karumuthil-Melethil, R. Li, B. S. Prabhakar, M. J. Holterman, and C. Vasu
Preferential Costimulation by CD80 Results in IL-10-Dependent TGF-{beta}1+-Adaptive Regulatory T Cell Generation
J. Immunol., May 15, 2008; 180(10): 6566 - 6576.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
N. Cassoux, A. Giron, B. Bodaghi, T. H. C. Tran, S. Baudet, F. Davy, C. C. Chan, P. Lehoang, and H. Merle-Beral
IL-10 Measurement in Aqueous Humor for Screening Patients with Suspicion of Primary Intraocular Lymphoma
Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3253 - 3259.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. G. Elpek, C. Lacelle, N. P. Singh, E. S. Yolcu, and H. Shirwan
CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model
J. Immunol., June 1, 2007; 178(11): 6840 - 6848.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. G. Zheng, J. H. Wang, W. Stohl, K. S. Kim, J. D. Gray, and D. A. Horwitz
TGF-beta Requires CTLA-4 Early after T Cell Activation to Induce FoxP3 and Generate Adaptive CD4+CD25+ Regulatory Cells
J. Immunol., March 15, 2006; 176(6): 3321 - 3329.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. Mocellin, F. M. Marincola, and H. A. Young
Interleukin-10 and the immune response against cancer: a counterpoint
J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Dercamp, K. Chemin, C. Caux, G. Trinchieri, and A. P. Vicari
Distinct and Overlapping Roles of Interleukin-10 and CD25+ Regulatory T Cells in the Inhibition of Antitumor CD8 T-Cell Responses
Cancer Res., September 15, 2005; 65(18): 8479 - 8486.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. Mukherjee, A. Ahmed, and D. Nandi
CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A
J. Leukoc. Biol., July 1, 2005; 78(1): 144 - 157.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. S. Kang and P. M. Allen
Priming in the Presence of IL-10 Results in Direct Enhancement of CD8+ T Cell Primary Responses and Inhibition of Secondary Responses
J. Immunol., May 1, 2005; 174(9): 5382 - 5389.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Chmielewski, A. Hombach, C. Heuser, G. P. Adams, and H. Abken
T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain above Threshold Does Not Increase T Cell Activation against Antigen-Positive Target Cells but Decreases Selectivity
J. Immunol., December 15, 2004; 173(12): 7647 - 7653.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Vasu, B. S. Prabhakar, and M. J. Holterman
Targeted CTLA-4 Engagement Induces CD4+CD25+CTLA-4high T Regulatory Cells with Target (Allo)antigen Specificity
J. Immunol., August 15, 2004; 173(4): 2866 - 2876.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. F. van der Sluijs, L. J. R. van Elden, M. Nijhuis, R. Schuurman, J. M. Pater, S. Florquin, M. Goldman, H. M. Jansen, R. Lutter, and T. van der Poll
IL-10 Is an Important Mediator of the Enhanced Susceptibility to Pneumococcal Pneumonia after Influenza Infection
J. Immunol., June 15, 2004; 172(12): 7603 - 7609.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.